Trending Now
Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) Receives IND From FDA Approving Clinical Study...
Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) has announced that the FDA has granted it an Investigational New Drug (IND), which will allow it to go on...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Akebia Therapeutics Inc. (NASDAQ:AKBA) Presents Positive INNO¬2VATE Phase 3 Clinical Vadadustat...
Akebia Therapeutics Inc. (NASDAQ:AKBA) has announced the presentation go its INNO2VATE Phase 3 clinical study data at the 2020 Reimagined American Society of Nephrology...
MAKE IT MODERN
LATEST REVIEWS
Seagen Inc. (NASDAQ: SGEN) Enters Licensing Agreement With RemeGen Co Ltd...
Seagen Inc. (NASDAQ: SGEN) has entered an exclusive global licensing agreement with RemeGen Co Ltd to develop and commercialize disitamab vedotin, a proprietary HER2-targeted...
MAKE IT MODERN
PERFORMANCE TRAINING
Royalty Pharma plc (NASDAQ: RPRX) Releases Q2 2021 Financial Results and Raises Full-Year Outlook
Royalty Pharma plc (NASDAQ: RPRX) announced its Q2 2021 financial results and raised its full-year 2020 adjusted cash receipts guidance.
Royalty Pharma reports Q2 2021...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi Announce Positive Pivotal Results of Second...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi have announced encouraging pivotal findings from the second phase three study, PRIME, evaluating Dupixent in adults with...
Tapping Recession-Proof Stocks to Fight the Bear (SNPS, KEGS, SAM, ABT, NEE, HD, ACN,...
Fed Chair Jay Powell took a trip to Capitol Hill this week for his regular interrogation by Congress – no doubt a...
Cellectar Biosciences Inc. (NASDAQ:CLRB) Receives Fast Track Designation For CLR 131 In Treatment Of...
Cellectar Biosciences Inc. (NASDAQ:CLRB) announced that the FDA has given Fast Track designation for CLR 131 in the treatment of Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL)...
Mind Medicine Inc. (NASDAQ: MNMD) Receives approval for IND to Continue MM-120 Dose-Optimization Study...
Mind Medicine Inc. (NASDAQ: MNMD) has announced that the US FDA has approved its Investigational New Drug application that allows the company...
MAKE IT MODERN
